This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evans, T. L. Search for Related Content PubMed PubMed Citation Articles by Evans, T. L.

Highlights from the Tenth World Conference on Lung Cancer

The University of Pennsylvania Medical Center—Presbyterian, Division of Hematology/Oncology, Philadelphia, Pennsylvania, USA

Correspondence: Tracey L. Evans, M.D., University of Pennsylvania Medical Center—Presbyterian, Division of Hematology/Oncology, Medical Arts Building Suite 103, 39th and Market Street, Philadelphia, Pennsylvania 19104, USA. Telephone: 215-662-8947; Fax: 215-243-3268; e-mail: tracey.evans{at}uphs.upenn.edu

Should adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC) be the standard of care? That question has been much debated since the presentation of results from the International Adjuvant Lung Cancer Trial (IALT) in May 2003 at the plenary session of the American Society of Clinical Oncology annual meeting. The IALT study showed a statistically significant survival advantage for patients treated with cisplatin-based adjuvant chemotherapy. The topic of adjuvant chemotherapy permeated the Tenth World Conference on Lung Cancer held from August 10–14, 2003 in Vancouver, Canada. Updated results of the IALT study were presented along with results from the Big Lung Trial from the United Kingdom and the Adjuvant Lung Project Italy trial, neither of which showed a significant survival benefit for adjuvant chemotherapy. How to put the IALT data into practice remains controversial, and leading lung cancer experts have not reached a consensus.

Platinum-based doublets that include a taxane, vinorelbine, or gemcitabine remain the standard of care for the first-line treatment of metastatic NSCLC. However, there may soon be a new option for second-line treatment. A randomized study of pemetrexed in the second-line setting found efficacy similar to that of docetaxel given every 3 weeks, with less toxicity.

Gefitinib was recently approved by the U.S. Food and Drug Administration for the treatment of advanced NSCLC following platinum-based chemotherapy and docetaxel. However, concerns have arisen about toxicity due to reports of interstitial pneumonitis from Japan. The observed incidence of interstitial pneumonitis from the data available to date is approximately 1%. Which patients derive the most benefit from gefitinib? It appears that lifetime nonsmokers and patients with bronchioloalveolar histology have the highest probability of disease response.

Key Words. Lung cancer • Adjuvant therapy • Pemetrexed • Gefitinib

This article has been cited by other articles:

				W. J. M. Hrushesky, J. Grutsch, P. Wood, Xiaoming Yang, E.-Y. Oh, C. Ansell, S. Kidder, C. Ferrans, D. F. T. Quiton, J. Reynolds, et al. Circadian Clock Manipulation for Cancer Prevention and Control and the Relief of Cancer Symptoms Integr Cancer Ther, December 1, 2009; 8(4): 387 - 397. [Abstract] [PDF]

				A. G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K. D. DILANA, E. M. KARAPANAGIOTOU, and K. N. SYRIGOS Therapy-induced Toxicity of the Lungs: An Overview Anticancer Res, February 1, 2009; 29(2): 631 - 639. [Abstract] [Full Text] [PDF]

				N. Ishikawa, Y. Daigo, A. Takano, M. Taniwaki, T. Kato, S. Hayama, H. Murakami, Y. Takeshima, K. Inai, H. Nishimura, et al. Increases of Amphiregulin and Transforming Growth Factor-{alpha} in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers Cancer Res., October 15, 2005; 65(20): 9176 - 9184. [Abstract] [Full Text] [PDF]

				A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella, P. P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, et al. EGFR Mutations in Non-Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment J. Clin. Oncol., February 1, 2005; 23(4): 857 - 865. [Abstract] [Full Text] [PDF]